News
September 18, 2024 – Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). >> Read More
December 27, 2023 – Stroke afflicts nearly 800,000 Americans each year and often results in cognitive impairment or death, leading to over $35 billion in annual healthcare costs in the United States. Neurexis Therapeutics is developing a neuroprotective drug, tatCN19o, for the prevention of brain damage following stroke. >> Read More
September 20, 2023 – Neurexis Therapeutics, a biotechnology company committed to reshaping the landscape of neuroprotection, is excited to highlight recent groundbreaking research that could unlock new avenues for Alzheimer’s disease and other brain disease therapies. >> Read More
August 4, 2023 – Acute CaMKII inhibition using the neuroprotective peptide tatCN19o did not affect pre-formed memories and only mildly and transiently interfered with learning. >> Read More
April 19, 2023 – Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II Small Business Innovation Research (SBIR) grant through the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health… >> Read More
March 7, 2022 – Let me start by saying that the last two years have been a case study on focusing on priorities and filtering out noise. I’m fortunate to work in an area where it’s easy to see the long-term value of what we do—advancing new technologies… >> Read More
October 14, 2021 – A promising approach for preventing cognitive and behavioral impairment following ischemic events such as cardiac arrest and stroke. Aurora, CO – Neurexis Therapeutics, Incorporated, announces it has been awarded >> Read More
January 4, 2021 – CBSA President & CEO, Jennifer Jones Paton, asked Michael Artinger, PhD, Neurexis’ Chief Executive Officer, CBSA’s Key Questions for Life Sciences Innovators. Neurexis Therapeutics relies on innovation to address a substantial unmet medical need: damage to the brain resulting from loss of blood flow >> Read More
June 18, 2020 – AURORA, CO – Neurexis Therapeutics, Inc. announced today that it has been approved for funding as part of the Colorado Office of Economic Development and International Trade’s (OEDIT) Advanced Industries Accelerator Program. The $250,000 Early Stage Capital and Retention Grant will be used to accelerate development of the company’s innovative therapeutic peptide >> Read More
April 8, 2020 – AURORA, CO – VIC Technology Venture Development, LLC (VIC) announced today the formation of Neurexis Therapeutics, Inc. to develop a new medication for the prevention of brain damage following ischemic events such as stroke. Licensed from the University of Colorado Anschutz Medical Campus >> Read More